SUANNUTRA and Myota: catalysing next-gen prebiotic solutions for Europe and the US

By Kevin Robinson | Published: 20-Jun-2025

Driving science-backed solutions for metabolic and gut health across continents, innovative partnerships are reshaping the prebiotic landscape. Dr Kevin Robinson recently caught up with two industry pioneers to find out more

You need to be a subscriber to read this article.
Click here to find out more.

The global prebiotic-fibre segment is surging as consumers look beyond basic gut health toward holistic benefits spanning metabolic, cardiovascular and even cognitive wellness.

In Europe alone, the prebiotic market was valued at $3.71 billion in 2024, is projected to reach $4.18 billion in 2025 and could climb to $10.77 billion by 2033 (at CAGR of approximately 12.6%).

Across the Atlantic, the US prebiotic-fibre segment stood at $1.45 billion in 2024, with forecasts predicting a rise to $2.35 billion by 2030 (CAGR ≈ 8.4%).

This double-digit growth underscores an urgent need for science-backed formulations that deliver proven multi-benefit functionality.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.

Subscribe now Already a subscriber? Sign in here.

You may also like